Related Experiment Videos
[Development of new drugs for urological cancers]
1Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba, Japan.
Abstract:
Urological cancers have a variety of biological characteristics. Thus, anti-cancer agents in this field are often developed focusing on the biological characteristics. For example, LH-RH agonist and anti-androgens have been developed for androgen-sensitive prostate cancer, interferons and IL-2 for renal cell cancer, and BCG for superficial bladder cancer. In this manuscript, new agents which are thought to be promising in the urological field, bropirimine for bladder cancer and liarozole for prostate cancer, are briefly introduced.
Insights
This study reviews novel anti-cancer agents for urological cancers. It introduces bropirimine for bladder cancer and liarozole for prostate cancer, highlighting their potential in treating these diseases.
Area of Science:
- Oncology
- Urology
- Pharmacology
Context:
- Urological cancers exhibit diverse biological characteristics necessitating targeted therapies.
- Current treatments include LH-RH agonists and anti-androgens for prostate cancer, interferons and IL-2 for renal cell cancer, and BCG for bladder cancer.
Purpose:
- To introduce promising new anti-cancer agents for urological malignancies.
- To discuss the development of novel therapeutic strategies based on tumor biology.
Summary:
- Reviews established treatments for urological cancers based on their specific biological features.
- Introduces bropirimine as a potential agent for bladder cancer treatment.
- Introduces liarozole as a potential agent for prostate cancer treatment.
Impact:
- Highlights novel therapeutic avenues for bladder and prostate cancer.
- Emphasizes the importance of biological targeting in developing urological cancer drugs.